Boehringer Ingelheim (BI) today announced results from the large, multi-national, randomized safety trial, which compared dual therapy with a novel oral anticoagulant (NOAC) to triple therapy with warfarin in non-valvular atrial fibrillation (NVAF) patients undergoing percutaneous coronary intervention (PCI) with stenting. The findings were presented in a late-breaking spotlight session at the European Society of Cardiology (ESC) Congress 2017 in Barcelona, and simultaneously published in the New England Journal of Medicine.  A press release from BI with additional study details is available here.